Shares of Amgen, Inc. (NASDAQ:AMGN) have been assigned an average rating of “Hold” from the twenty-one research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $207.89.

Several research firms have recently issued reports on AMGN. Royal Bank of Canada reaffirmed a “neutral” rating and issued a $192.00 price target on shares of Amgen in a research report on Tuesday, May 21st. Mizuho reaffirmed a “buy” rating and issued a $211.00 price target on shares of Amgen in a research report on Tuesday, February 26th. JPMorgan Chase & Co. reaffirmed a “hold” rating and issued a $190.00 price target on shares of Amgen in a research report on Wednesday, May 15th. BidaskClub lowered Amgen from a “buy” rating to a “hold” rating in a research report on Wednesday, February 20th. Finally, Citigroup raised Amgen from a “neutral” rating to a “buy” rating and lowered their price target for the stock from $211.00 to $205.00 in a research report on Wednesday, May 22nd.

Amgen stock traded down $2.34 on Tuesday, hitting $166.70. 2,808,629 shares of the stock traded hands, compared to its average volume of 2,619,590. The company has a current ratio of 2.77, a quick ratio of 2.53 and a debt-to-equity ratio of 2.71. The firm has a market capitalization of $103.10 billion, a P/E ratio of 11.58, a P/E/G ratio of 2.23 and a beta of 1.15. Amgen has a 1 year low of $166.30 and a 1 year high of $210.19.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, April 30th. The medical research company reported $3.56 EPS for the quarter, beating the consensus estimate of $3.45 by $0.11. The business had revenue of $5.56 billion during the quarter, compared to analyst estimates of $5.55 billion. Amgen had a return on equity of 71.02% and a net margin of 34.00%. The company’s revenue for the quarter was up .1% on a year-over-year basis. During the same quarter last year, the firm posted $3.47 earnings per share. Analysts predict that Amgen will post 13.94 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be given a $1.45 dividend. This represents a $5.80 dividend on an annualized basis and a yield of 3.48%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is 40.28%.

In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $175.73, for a total value of $351,460.00. Following the completion of the transaction, the director now owns 15,092 shares of the company’s stock, valued at approximately $2,652,117.16. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last three months, insiders sold 6,000 shares of company stock valued at $1,115,580. 0.25% of the stock is owned by insiders.

A number of large investors have recently modified their holdings of AMGN. Mackey Komara & Dankovich LLC bought a new stake in shares of Amgen during the 1st quarter valued at about $25,000. Ruggie Capital Group grew its stake in shares of Amgen by 297.1% during the 4th quarter. Ruggie Capital Group now owns 135 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 101 shares during the period. Capital Financial Planning LLC bought a new stake in shares of Amgen during the 4th quarter valued at about $27,000. Massey Quick Simon & CO. LLC grew its stake in shares of Amgen by 710.5% during the 4th quarter. Massey Quick Simon & CO. LLC now owns 154 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 135 shares during the period. Finally, Strategy Asset Managers LLC bought a new stake in shares of Amgen during the 1st quarter valued at about $30,000. 77.31% of the stock is owned by institutional investors and hedge funds.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Further Reading: What is a Buy-Side Analyst?

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.